(Q33955172)

30 July 2017

1 reference

title

Complete estrogen blockade for the treatment of metastatic and early stage breast cancer (English)

1 reference

30 July 2017

Michaud LB

1

1 reference

30 July 2017

Buzdar AU

series ordinal

2

1 reference

30 July 2017

publication date

1 April 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

16

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

261-271

1 reference

Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.

30 July 2017

cites work

1 reference

12 December 2020

Zoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancer.

1 reference

12 December 2020

Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells.

1 reference

12 December 2020

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer

1 reference

12 December 2020

Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments

1 reference

12 December 2020

Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat

1 reference

12 December 2020

Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma

1 reference

12 December 2020

Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London

1 reference

12 December 2020

Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer

1 reference

12 December 2020

Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer

1 reference

12 December 2020

Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer

1 reference

12 December 2020

Combined effects of Buserelin, estradiol and Tamoxifen on the growth of MCF-7 human breast cancer cells in vitro

1 reference

12 December 2020

Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells

1 reference

12 December 2020

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions

1 reference

12 December 2020

Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats

1 reference

12 December 2020

Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against.

1 reference

12 December 2020

LHRH agonists and human breast cancer cells

1 reference

12 December 2020

Failure to detect gonadotrophin-releasing hormone receptors in human benign and malignant breast tissue and in MCF-7 and MDA-MB-231 cancer cells

1 reference

12 December 2020

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer

1 reference

12 December 2020

Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

1 reference

12 December 2020

Resistance of the ovary to blockade of aromatization with aminoglutethimide

1 reference

12 December 2020

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer

1 reference

12 December 2020

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer

1 reference

12 December 2020

Combined goserelin and tamoxifen in premenopausal advanced breast cancer: duration of response and survival

1 reference

12 December 2020

Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer

1 reference

12 December 2020

Predictors of response to second-line endocrine therapy for breast cancer

1 reference

12 December 2020

Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin)--lack of shrinkage of uterine fibroids

1 reference

12 December 2020

Differential effects of LHRH and somatostatin analogs on human breast cancer

1 reference

12 December 2020

Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats

1 reference

12 December 2020

Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.

1 reference

12 December 2020

Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer

1 reference

12 December 2020

Zoladex in the treatment of premenopausal metastatic breast cancer patients.

1 reference

12 December 2020

The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer--a 5-year experience and further endocrine therapies. Cooperative German Zoladex Study Group

1 reference

12 December 2020

Changes in serum estrogen levels in women during tamoxifen therapy

1 reference

12 December 2020

Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.

1 reference

12 December 2020

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology

1 reference

12 December 2020

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer

1 reference

12 December 2020

Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.

1 reference

12 December 2020

Gonadotropin-releasing hormone binding sites in human breast carcinoma

1 reference

12 December 2020

Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer

1 reference

12 December 2020

Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study

1 reference

12 December 2020

LHRH-Agonist treatment in clinical and experimental human breast cancer

1 reference

12 December 2020

Endocrine and Therapeutic Effects of Aminoglutethimide in Premenopausal Patients with Breast Cancer

1 reference

12 December 2020

10.2165/00002512-200016040-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1018739848

0 references

1 reference